Pulmonary Manifestations and Vascular Changes in Pediatric Transplantation-Associated Thrombotic Microangiopathy

• Published in: Transplantation and cellular therapy Vol. 29; no. 1; pp. 45.e1 - 45.e8
• Main Authors: Schoettler, Michelle L., Saldana, Blachy D., Berkenkamp, Lisa, Chonat, Satheesh, Watkins, Benjamin, Rotz, Seth J., Simons, Dawn, Graf, Emily, Rossi, Christopher, Cheng, Jinjun, Hammers, Yuki A., Rytting, Heather, Williams, Kirsten M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2023
• Subjects: Child; Diffuse alveolar hemorrhage (DAH); Eculizumab; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation - adverse effects; Hemorrhage - complications; Humans; Hypertension, Pulmonary - complications; Lung - pathology; Lung Diseases - complications; Lung Diseases - therapy; Pneumonia - complications; Pulmonary hypertension; Pulmonary TA-TMA; Retrospective Studies; Thrombosis - complications; Thrombotic Microangiopathies - diagnosis; Thrombotic Microangiopathies - etiology; Thrombotic Microangiopathies - therapy; Transplant associated thrombotic microangiopathy (TA-TMA); Eculizumab; Transplant associated thrombotic microangiopathy (TA-TMA); Pulmonary TA-TMA; Pulmonary hypertension; Diffuse alveolar hemorrhage (DAH)
• ISSN: 2666-6367; 2666-6367
• DOI: 10.1016/j.jtct.2022.09.026

•We report pulmonary vascular changes in 10 children with transplant-associated thrombotic microangiopathy.•Only 2 of the 10 children had evidence of pulmonary hypertension on echocardiography.•Nine children had diffuse alveolar hemorrhage on histology.•Outcomes were poor despite early therapy with eculizumab. Although transplant-associated thrombotic microangiopathy (TA-TMA) commonly complicates pediatric hematopoietic cellular therapy (HCT), pulmonary manifestations and histology of TA-TMA (pTA-TMA) are rarely reported, with scant data available on timing, risk factors, pathogenesis, and outcomes. Pulmonary hypertension (PH) and diffuse alveolar hemorrhage (DAH) are recognized manifestations of pTA-TMA. The objective of this study was to characterize the pathologic findings, outcomes, and coincident diagnoses preceding biopsy-proven pTA-TMA. In Institutional Review Board- approved retrospective studies, available lung tissue was reviewed at 2 institutions between January 2016 and August 2021 to include those with pulmonary vascular pathology. Histologic features of pTA-TMA were present in 10 children with prior respiratory decline after an allogeneic HCT (allo-HCT; n = 9) or autologous HCT (n = 1). Pathologic lesions included muscular medialization, microthrombi, and red cell fragments, in addition to perivasculitis and intimal arteritis. Parenchymal findings included diffuse alveolar damage, organizing pneumonia, and plasmocytic infiltrates. Six children were clinically diagnosed with TA-TMA, and all were treated with eculizumab, at a median of 2.5 days after clinical diagnosis (range, 0 to 11 days). Four were identified postmortem. Coincident pulmonary infection was confirmed in 8 of the 10 patients. Five allo-HCT recipients (56%) experienced graft-versus-host disease (GVHD; 4 acute, 1 chronic) prior to the onset of respiratory symptoms. Two patients (20%) had clinically recognized DAH, although 9 (90%) had evidence of DAH on histology. Although all 10 patients underwent echocardiography at the time of symptom onset and 9 had serial echocardiograms, only 2 patients had PH detected. Treatments varied and included sildenafil (n = 3), steroids (n = 1), and eculizumab (n = 6). One patient was alive at the time of this report; the remaining 9 died, at a median of 52 days after onset of respiratory symptoms (range 4 to 440 days) and a median of 126 days post-HCT (range, 13 to 947 days). pTA-TMA is a heterogeneous histologic disease characterized by arteriolar inflammation, microthrombi, and often DAH. pTA-TMA presented with respiratory decline with systemic TA-TMA in all patients. Clinicians should maintain a high degree of suspicion for DAH in patients with TA-TMA and pulmonary symptoms. Coincident rates of GVHD and pulmonary infections were high, whereas the rate of PH identified by echocardiography was 20%. Outcomes were poor despite early use of eculizumab and other therapies. Our data merit consideration of pTA-TMA in patients with acute respiratory decline in the setting of systemic TA-TMA, GVHD, and infection. Investigation of additional therapies for pTA-TMA is needed as well. © 2022 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. [Display omitted]